The first twice-daily injectable HIV prevention drug based on lenacapavir has received CHMP recommendation for authorization, promising an effective and affordable solution.
Cristina Petrache
Health
Foto pexels.com
Always see our news on Google
Lenacapavir is the first twice-daily injectable drug for the prevention of HIV infection, with 99.9% efficacy in clinical trials. Recommended by the CHMP, this treatment simplifies prevention by eliminating the need for daily tablets. In Romania, where the cost of HIV treatment is high, the new PrEP could reduce costs and improve access for vulnerable people. Approved at European level, this drug represents a significant opportunity to transform HIV prevention into public health policy.
Sources
Europa se apropie de aprobarea primului tratament PrEP injectabil cu administrare la 6 luni - o şansă uriaşă pentru prevenţia HIV în România
Europa se apropie de aprobarea primului tratament PrEP injectabil cu administrare la 6 luni - o șansă uriașă pentru prevenția HIV în România
Omenirea, mai aproape ca niciodată de a opri virusul HIV. Europa a autorizat tratamentul revoluționar
E.U. regulator approves injectable HIV drug that experts say could help stop transmission
EU regulator approves injectable HIV drug that experts say could help stop transmission
Latest News
11:38
VAT fraud accounted for almost 65% of the estimated damages in the 3,602 active investigations of the EPPO at the end of 2025
11:32
One in four Europeans buy tickets online, and Romania has the second lowest share in the EU.
11:32
Armed attack at a school in Thailand: Six dead and 15 injured after a student opened fire / The alleged perpetrator committed suicide
11:27
European projects use AI and Copernicus data to anticipate fires and estimate urban emissions
11:26
ANM announces high temperatures and atmospheric instability in the next 48 hours
See more news
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
